Cabaletta bio reports positive initial clinical data from phase 1/2 reset-myositis™ and reset-sle™ trials of caba-201

– no crs, icans, infections or serious adverse events observed in either of the first two patients through data cut-off of may 28, 2024 –

SLE Ratings Summary

SLE Quant Ranking